Panbela Therapeutics, Inc. (PBLA)

NASDAQ: PBLA · IEX Real-Time Price · USD
1.120
+0.010 (0.90%)
At close: Feb 23, 2024, 4:00 PM
1.150
+0.030 (2.68%)
After-hours: Feb 23, 2024, 7:58 PM EST
0.90%
Market Cap 5.44M
Revenue (ttm) n/a
Net Income (ttm) -23.51M
Shares Out 4.86M
EPS (ttm) 3,051.23
PE Ratio 0.00
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 271,397
Open 1.130
Previous Close 1.110
Day's Range 1.090 - 1.140
52-Week Range 1.060 - 888.000
Beta 0.84
Analysts Strong Buy
Price Target 415.00 (+36,953.57%)
Earnings Date Mar 14, 2024

About PBLA

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibi... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 6
Stock Exchange NASDAQ
Ticker Symbol PBLA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for PBLA stock is "Strong Buy." The 12-month stock price forecast is $415.0, which is an increase of 36,953.57% from the latest price.

Price Target
$415.0
(36,953.57% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Top 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: OSAGRISINT
2 days ago - Benzinga

Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements

MINNEAPOLIS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with ur...

10 days ago - GlobeNewsWire

Panbela Announces Closing of Approximately $9.0 Million Public Offering

MINNEAPOLIS, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet me...

24 days ago - GlobeNewsWire

Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)

MINNEAPOLIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients wi...

26 days ago - GlobeNewsWire

Panbela Announces Pricing of Approximately $9.0 Million Public Offering

MINNEAPOLIS, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet me...

27 days ago - GlobeNewsWire

Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum

MINNEAPOLIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet me...

4 weeks ago - GlobeNewsWire

Panbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial

A Phase 1 clinical study showed that high dose DFMO treatment in combination with chemotherapy may provide therapeutic benefits to heavily pretreated patients with neuroblastoma. A Phase 1 clinical st...

5 weeks ago - GlobeNewsWire

Panbela Announces 1-for-20 Reverse Stock Split Effective January 18, 2024

MINNEAPOLIS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet me...

5 weeks ago - GlobeNewsWire

Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.0 Million Gross Proceeds Priced At-the-Market

MINNEAPOLIS, Dec. 21, 2023 (GLOBE NEWSWIRE) --  Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients w...

2 months ago - GlobeNewsWire

Panbela Therapeutics' stock tumbles, after more than tripling the past 2 days

Shares of Panbela Therapeutics Inc. PBLA, +55.45% dropped 21.7% in premarket trading, as they paused after a two-day “meme”-like rally of 243.5%. The two-day rally in the biopharmaceutical company's s...

2 months ago - Market Watch

Panbela Therapeutics' stock skyrockets after positive FDA news on child cancer treatment

Shares of Panbela Therapeutics Inc. skyrocketed again Tuesday, following positive news from the U.S. Food and Drug Administration regarding a treatment for child cancer.

2 months ago - Market Watch

Panbela Therapeutics Announces US WorldMeds NDA Approval for Eflornithine (DFMO) in Pediatric Neuroblastoma

MINNEAPOLIS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet me...

2 months ago - GlobeNewsWire

Panbela Announces Publication of Abstract Titled: Evaluation of Myeloma Cell Lines Viability Following Administration of SBP-101 and DFMO Polyamine Inhibitors

MINNEAPOLIS, Dec. 04, 2023 (GLOBE NEWSWIRE) --   Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet ...

2 months ago - GlobeNewsWire

Panbela Announces 2nd Independent Safety Review of the ASPIRE Registration Clinical Trial: Recommended Continuation with no Trial Modification

MINNEAPOLIS, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet me...

3 months ago - GlobeNewsWire

Panbela Provides Business Update and Reports Q3 2023 Financial Results

MINNEAPOLIS, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet me...

3 months ago - GlobeNewsWire

Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds Priced At-the-Market

MINNEAPOLIS, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients wi...

4 months ago - GlobeNewsWire

Panbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves β Cell Function in Type 1 Diabetes

MINNEAPOLIS, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients wi...

4 months ago - GlobeNewsWire

Panbela Announces Validation of European Patent in UK, Italy, Germany, France, and Spain for Claims of a Novel Process for the Production of SBP-101

MINNEAPOLIS, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients wi...

4 months ago - GlobeNewsWire

Acceptance of Polyamine Inhibitor CAR-T Combination Abstract for Online Publication

MINNEAPOLIS, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet me...

4 months ago - GlobeNewsWire

Panbela to Host Third Quarter 2023 Earnings Conference Call on November 9, 2023

MINNEAPOLIS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet me...

4 months ago - GlobeNewsWire

Panbela Announces Issuance of New Patent in China for Claims of a Novel Process for the Production of SBP-101

MINNEAPOLIS, Sept. 26, 2023 (GLOBE NEWSWIRE) --  (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical n...

5 months ago - GlobeNewsWire

Panbela to Present at the LD Micro Investor Conference

MINNEAPOLIS, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients w...

5 months ago - GlobeNewsWire

Panbela Announces Issuance of New Patent in Chile for Claims of a Novel Process for the Production of Flynpovi

MINNEAPOLIS, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients w...

6 months ago - GlobeNewsWire

Panbela to Present at H.C. Wainwright 25th Annual Global Investment Conference

MINNEAPOLIS, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients wi...

6 months ago - GlobeNewsWire

Panbela Announces Issuance of New Patent in Europe for Claims of a Novel Process for the Production of SBP-101

MINNEAPOLIS, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients wi...

6 months ago - GlobeNewsWire